Clinical Trial

PENTHROXâ„¢ in the Canadian Emergency Department (ED)

Study Description

PENTHROXâ„¢ in the Canadian Emergency Department (ED)

This Canadian, multi-centre, prospective, real world study is designed to evaluate the effectiveness of low dose methoxyflurane (MEOF) (PENTHROXa"c) for the treatment of moderate to severe pain associated with trauma in the Canadian ED.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Methoxyflurane 3mL

As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROXâ„¢ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROXâ„¢ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROXâ„¢ inhaler with the Activated Carbon (AC) chamber.

Additional Information

Official Study Title

A Phase IV Real World Study on the Use of Low Dose Methoxyflurane (PENTHROXâ„¢) for the Treatment of Moderate to Severe Trauma Pain in the Canadian Emergency Department

Clinical Trial ID

NCT03868436

ParticipAid ID

bo2mka